Form 4: Coherus Oncology Director Granted 112,000 Stock Options

Coherus Oncology, Inc. Director Lee Nisley Newcomer was granted 112,000 stock options with an exercise price of $0.7904, vesting over one year.

Summary

• Lee Nisley Newcomer, a Director of Coherus Oncology, Inc. (CHRS), was granted 112,000 stock options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these stock options is $0.7904 per share.
• The options are scheduled to vest as to 100% of the total number of shares on the one-year anniversary of June 11, 2025 (i.e., June 11, 2026).
• Vesting is contingent upon the Reporting Person's continued service relationship with Coherus Oncology, Inc. on the vesting date.
• The expiration date for these stock options is June 12, 2035.
• Following this transaction, Lee Nisley Newcomer beneficially owns 112,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options is a positive incentive for the director, aligning their interests with the company's long-term performance, which is generally viewed as a neutral to slightly positive event for the company.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company and shareholder value creation.
• This is a standard form of equity compensation, indicating ongoing commitment to incentivizing key personnel.

Risks

• The vesting of the stock options is subject to the Reporting Person's continued service relationship with the Issuer, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The stock option grant provides a future incentive for the director, with vesting contingent on continued service, aligning their long-term interests with the company's performance.

Industry Context

This Form 4 filing details an individual director's equity compensation, which is a standard practice across industries, particularly in biotechnology and pharmaceuticals, to align management and director interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of equity compensation in the biotechnology and pharmaceutical industry, aiming to align the director's long-term interests with the company's performance and shareholder value.
• The specific terms, such as the exercise price and vesting schedule, are typical for such grants, though the number of options would vary based on company size, director role, and compensation philosophy within the sector.

Related Party Transactions

• The grant of 112,000 stock options to Lee Nisley Newcomer, a Director of Coherus Oncology, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with shareholder value creation, as the options gain value if the company's stock price increases.

Next Steps

• The options are scheduled to vest on June 11, 2026, subject to the director's continued service.

Key Dates

Keywords

Coherus Oncology, CHRS, Stock Option Grant, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Lee Nisley Newcomer